J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc (NASDAQ:AMRX), noting the company’s generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio.
In August 2024, the FDA approved Amneal’s IPX203 for Parkinson’s disease as…